Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.00 EUR
Change Today 0.00 / 0.00%
Volume 3.6K
As of 4:19 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

epigenomics ag (ECX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - €6.92
52 Week Low
10/14/14 - €2.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EPIGENOMICS AG (ECX)

Related News

No related news articles were found.

epigenomics ag (ECX) Related Businessweek News

No Related Businessweek News Found

epigenomics ag (ECX) Details

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer, which relies on its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung BL Reflex Assay, a confirmatory test that aids in the diagnosis of lung cancer. Its development pipeline also contains tests for screening, monitoring, diagnosis, and prognosis assessment in colorectal, lung, and prostate cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

38 Employees
Last Reported Date: 08/3/15
Founded in 1998

epigenomics ag (ECX) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: €377.3K
Chief Operating Officer and Member of Executi...
Total Annual Compensation: €300.0K
Compensation as of Fiscal Year 2014.

epigenomics ag (ECX) Key Developments

Epigenomics AG Presents at 13th SCC Small Cap Conference, Aug-31-2015 03:40 PM

Epigenomics AG Presents at 13th SCC Small Cap Conference, Aug-31-2015 03:40 PM. Venue: DVFA Center, Mainzer Landstr. 37-039, 60329 Frankfurt am Main, Germany. Speakers: Thomas Taapken, Chief Executive Officer, Chief Financial Officer and Member of Executive Board.

Epigenomics AG Announces Earnings Results for Second Quarter Ended June 2015; Reiterates Earnings Guidance for the Year 2015

Epigenomics AG announced earnings results for second quarter ended June 2015. Net loss in the second quarter of 2015 expanded to EUR 2.5 million due to higher operating costs. In the second quarter of 2014, net loss stood at EUR 1.8 million. LBIT reached EUR 2.6 million after EUR 1.6 million in the second quarter of 2014. Revenue increased to EUR 487 million from EUR 405 million, due to a 36% increase in product sales. The company reiterated its earnings guidance for 2015 full-year revenue of EUR 3 million to EUR 4 million, and LBIT in the range of EUR 10 million and EUR 11 million.

Epigenomics AG, Q2 2015 Earnings Call, Aug 06, 2015

Epigenomics AG, Q2 2015 Earnings Call, Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECX:GR €5.00 EUR 0.00

ECX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ECX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIGENOMICS AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at